PODCAST

Healthcare Policy

ReachMD

science & medicine medicine

All Episodes

00:00:00

The FDA's Safe Use Initiative

Healthcare Policy ·

2010/03/24

Host: Charles Turck, PharmD, BCPS, BCCCP Host Dr. Charles Turck talks with Dr. Karen Weiss, project lead for the FDA's Safe Use Initiative, and Dr. Dale Slavin, senior policy analyst. How is the FDA working to ensure that medications are used optimally once they’re available to the public? This program explains this collaborative initiative to address various types of preventable harm from medications.

00:00:00

The Benefits of TZDs for Early Type 2 Diabetes

Healthcare Policy ·

2010/03/11

Guest: John (Jack) L. Leahy, MD Host: Steven Edelman, MD Where do thiazolidinediones, or TZD's, fit in our clinical approach to treating patients with type 2 diabetes? TZD's used early in the course of the disease seem to be a powerful therapy with a substantial reduction in the progression of type 2 diabetes. What does this tell us about the pathogenesis of diabetes? Join host Dr. Steven Edelman and his guest, professor of medicine and chief of the division of endocrinology,

00:00:00

Oral Agents for Diabetes: What to Choose and When

Healthcare Policy ·

2010/03/11

Guest: Andrew Ahmann, MD Host: Steven Edelman, MD We now have many choices of oral agents in the treatment of type 2 diabetes patients. But choosing the type and where they fit in the treatment algorithm can be a challenge. Join host Dr. Steven Edelman and his guest, director of the Harold Schnitzer Diabetes Health Center, Dr. Andrew Ahmann, as they discuss the different classes of oral agents, benefits and treatment algorithms in the treatment of type 2 diabetes.

00:00:00

The Battle Continues Against Pharmacological Cheating...

Healthcare Policy ·

2010/03/04

Guest: Gary Wadler, MD Host: Bruce Japsen Even after steroids scandals in Major League Baseball and more than 30 athletes were withheld from the winter Olympics in Vancouver for breaking anti-doping rules, why do athletes still engage in pharmacological cheating? The latest concern among sport officials is a new erythropoietin called Hematide, still in investigate trials.Dr.Gary Wadler, chairman of the World Anti-Doping Agency's Prohibited List and Methods Sub-Committee, talks to

00:00:00

Rewriting the DSM

Healthcare Policy ·

2010/02/23

Guest: Darrel Regier, MD Host: Bruce Japsen It's been over 15 years since the publication of the Fourth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). The DSM-V is due to be published in May 2013, and for the first time, the American Psychiatric Association invited input from the wider medical community and the general public. Anyone could go to the website, view the draft criteria alongside DSM-IV criteria, as well as the rationale behind the

00:00:00

Multiple Choice: Customizing Insulin Therapy

Healthcare Policy ·

2010/02/23

Guest: Matthew Riddle, MD Host: Steven Edelman, MD Multiple choices of insulin therapy have provided a decided advantage to both the healthcare provider and patient living with diabetes. What are the specific benefits of customizing insulin therapy for our patients? Join host Dr. Steven Edelman and his guest, professor of medicine at Oregon Health & Science University, Dr. Matthew Riddle, as they discuss the benefits of standard versus individualized insulin therapy.

00:00:00

As Prescribed: Meeting the Challenges of Medication...

Healthcare Policy ·

2010/01/19

Host: Janet Wright, MD Guest: Michael Ho, MD, PhD Medication adherence is a significant problem in the US. Patients with chronic conditions such as hypertension or high cholesterol can be particularly susceptible to non-adherence, because patients may not experience symptoms that would seem to justify taking medication, and thus may not notice any immediate benefits from their medications. What are some of the other barriers to medication adherence? Dr. Michael Ho, associate

00:00:00

In-Office Drug Testing for Retinal Conditions

Healthcare Policy ·

2010/01/06

Host: Roy Levit, MD Guest: Allen Verne, MD What are the advantages to using private practices, as opposed to academic institutions, for testing medications? Dr. Allen Verne, president of the American Retina Foundation and founder of the Bay Area Retina Associates, discusses in-office drug studies he is involved in, including one on diabetic retinopathy and another on photodynamic therapy, and why these studies can be particularly useful in determining the most effective treatments

00:00:00

Clinical Care Implications of ALLHAT

Healthcare Policy ·

2009/12/23

Guest: Debra Simmons, MD Host: Steven Edelman, MD The ALLHAT hypertension study results indicated that less costly, traditional diuretics are more effective than newer medicines at lowering high blood pressure and preventing some forms of heart disease. Join host Dr. Steven Edelman and his guest, endocrinologist and director of the endocrinology, diabetes and metabolism training program at the University of Arkansas Medical Sciences and Central Arkansas Veterans Healthcare System,

00:00:00

The Potential of Immunotherapy in Type 1 Diabetes

Healthcare Policy ·

2009/12/23

Guest: Matthias von Herrath, MD Host: Steven Edelman, MD Development of a combination therapy is showing significant promise in type 1 diabetes when caught in the early stages. What are some immuno-therapies currently being evaluated for treating type 1 diabetes? Join host Dr. Steven Edelman and his guest, director of the Center for Type 1 Diabetes Research at the La Jolla Institute for Allergy and Immunology, Dr. Matthias von Herrath, as they discuss histopathology,

00:00:00

Emerging Insulin Pump Technology

Healthcare Policy ·

2009/12/22

Guest: Nancy Bohannon, MD Host: Steven Edelman, MD Will insulin pumps become the preferred therapy for patients with type 2 diabetes who are not at goal? New insulin pump technology and patch pumps are offering a whole new level of customization, an ability to improve glucose control and quality of life. Join host Dr. Steven Edelman and his guest, endocrinologist and director of clinical research at St. Luke’s Hospital, Dr. Nancy Bohannon as they discuss new insulin pump

00:00:00

Interventions Targeting Impaired Glucose Tolerance

Healthcare Policy ·

2009/11/20

Guest: Robert Henry, MD Host: Steven Edelman, MD The ACT NOW study examined whether treatment of impaired glucose tolerance in pre-diabetic patients with pioglitazone could prevent or delay the development of type 2 diabetes. Join host Dr. Steven Edelman and his guest, endocrinologist and professor of medicine at the University of California San Diego, Dr. Robert Henry, as they discuss the results and implications for clinical care.

00:00:00

The ARBITER 6-HALTS Trial: Clinical Implications

Healthcare Policy ·

2009/11/18

Guest: Christopher Cannon, MD Host: Jack Lewin, MD Previous trials, including the ENHANCE trial, have raised doubts about the clinical benefits of adding ezetimibe to high-dose statin therapy. The ARBITER 6-HALTS trial added further weight to the results of ENHANCE, wherein the ARBITER trial demonstrated that extended-release niacin was superior to ezetimibe as adjunctive therapy to high-dose statins in slowing atherosclerosis. However, this study was not based on clinical

00:00:00

Health Care Reform in Perspective: Part 3

Healthcare Policy ·

2009/11/04

President Barack Obama has placed US healthcare reform at the top of his domestic agenda, and months of legislative work on the issue have resulted in five bills — three in the House of Representatives and two in the Senate — that proponents believe will move the country in the direction of universal coverage, a fairer insurance system, and slower escalation of health care costs. In part 3 of a symposium co-sponsored by the Journal and the Harvard School of Public Health, health policy

00:00:00

Health Care Reform in Perspective: Part 2

Healthcare Policy ·

2009/11/04

President Barack Obama has placed US healthcare reform at the top of his domestic agenda, and months of legislative work on the issue have resulted in five bills — three in the House of Representatives and two in the Senate — that proponents believe will move the country in the direction of universal coverage, a fairer insurance system, and slower escalation of health care costs. In part 2 of a symposium co-sponsored by the Journal and the Harvard School of Public Health, health policy

00:00:00

Health Care Reform in Perspective: Part 1

Healthcare Policy ·

2009/11/04

President Barack Obama has placed US healthcare reform at the top of his domestic agenda, and months of legislative work on the issue have resulted in five bills — three in the House of Representatives and two in the Senate — that proponents believe will move the country in the direction of universal coverage, a fairer insurance system, and slower escalation of healthcare costs. In Part 1 of a symposium co-sponsored by the Journal and the Harvard School of Public Health (HSPH), health

00:00:00

How Will Pharmacogenomics Play a Role in Diabetes...

Healthcare Policy ·

2009/10/09

Guest: Joseph Ma, PharmD Host: Steven Edelman, MD Pharmacogenomics is applied to select medications with the goal of optimizing drug therapy: maximizing efficacy, minimizing toxicity, and minimizing pharmacokinetic and pharmacodynamic variability. Join guest host, Dr. Candis Morello andDr. Joseph Ma,assistant professor of clinical pharmacy at the University of San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, as they discuss the impact of pharmacogenomics in diabetes

00:00:00

DPP-4 Inhibitors: A New Class of Medications

Healthcare Policy ·

2009/10/09

Guest: Lisa Kroon, PharmD, CD Host: Steven Edelman, MD The new class of medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which stimulate the pancreas to make more insulin after eating a meal, may be changing the way we treat people with type 2 diabetes. Join guest host, Dr. Candis Morello and her guest, professor of clinical pharmacy in the School of Pharmacy at the University of California San Francisco, Dr. Lisa Kroon, as they discuss the use of DPP-4 therapy in

00:00:00

Healthcare and the Recession

Healthcare Policy ·

2009/10/08

The US economy has been in recession for more than a year, the unemployment rate is climbing, the ranks of the uninsured are growing rapidly, and healthcare provider organizations are feeling the squeeze. What help can the federal government offer as part of the economic stimulus package? What will the increasing pressure mean for proposed healthcare reforms? And is there any silver lining in the clouds for the future of the US healthcare system? In a roundtable discussion moderated by Dr

00:00:00

Physicians and Execution - Part 2

Healthcare Policy ·

2009/10/08

In this continuing roundtable discussion, moderator Dr. Atul Gawande, surgeon and associate professor at Harvard Medical School and the Harvard School of Public Health, is joined by Deborah Denno, professor of law at Fordham University; Dr. Robert Truog, professor of medical ethics, anesthesiology, and pediatrics at Harvard Medical School; and Dr. David Waisel, associate professor of anesthesia at Harvard Medical School, in a conversation about lethal injection, the current protocol,

323 results

Healthcare Policy

All Episodes

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事